An overview on inactivated and live-attenuated SARS-CoV-2 vaccines

Khoshnood, Saeed and Arshadi, Maniya and Akrami, Sousan and Koupaei, Maryam and Ghahramanpour, Hossein and Shariati, Aref and Sadeghifard, Nourkhoda and Heidary, Mohsen (2022) An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. Journal of Clinical Laboratory Analysis, 36 (5).

Full text not available from this repository. DOI: UNSPECIFIED


After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS�CoV�2), first infections were detected in Wuhan city of China in December 2019, which was followed by a worldwide pandemic with a record of 5.41 million deaths. Due to urgent need for the development of a safe and effective vaccine for coronavirus disease 2019 (COVID-19), attempts for producing efficient vaccines are inexhaustibly continuing. According to a report by the World Health Organization (WHO) on COVID-19 vaccine tracker and landscape, there are 149 vaccine candidates all over the world. Inactivated SARS-CoV-2 vaccines as a conventional vaccine platform consist of whole virus particles grown in cell culture and inactivated by chemicals. Because of benefits such as antigenic similarity to real virion inducing humoral and cellular immune responses and ease for transport and storage, these vaccines, including the vaccines produced by Bharat Biotech, Sinopharm, and Sinovac, are in use at large scales. In this study, we have a review on inactivated SARS-CoV-2 vaccines that are passing their phase 3 and 4 clinical trials, population which was included in the trials, vaccine producers, the efficiency, adverse effects, and components of vaccines, and other vaccine features.

Item Type: Article
Uncontrolled Keywords: COVID-19,SARS-CoV-2,attenuated vaccine,inactivated vaccine,review
Subjects: Medicine
Pharmacology, Toxicology and Pharmaceutics
Depositing User: editor . 5
Date Deposited: 04 Apr 2023 11:25
Last Modified: 04 Apr 2023 11:25

Actions (login required)

View Item View Item